Abstract:
The present invention relates to a method of preventing and treating chronic hepatitis and other liver diseases comprising administering a blocker of Light, LTα1 β2, LTα2β1 or LTβR, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating chronic hepatitis and other liver diseases.
Abstract:
The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described.
Abstract:
The present invention relates to methods of treating and/or preventing obesity comprising the administration of an inhibitor of lymphotoxin, IL-22 and/or IL-23 to a subject having or at risk of developing obesity.
Abstract:
The present invention relates to a method of preventing and treating chronic hepatitis and other liver diseases comprising administering a blocker of Light, LTa1ß2, LTa2ß1 or LTßR, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating chronic hepatitis and other liver diseases.
Abstract:
The invention provides various antibodies that bind to lymphotoxin-a, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies
Abstract:
This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
Abstract:
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Abstract:
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Abstract:
The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LTβR signaling are also provided.